220731-04-4

Basic information

• Product Name: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl 5-aminopyridin-2-ylcarbamate;Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester;tert-Butyl (5-aminopyridin-2-yl);tert-Butyl N-(5-aminopyridin-2-yl)carbamate
• CAS NO: 220731-04-4
• Molecular Formula: C₁₀H₁₅N₃O₂
• Molecular Weight: 209.245
• Product Categories: N-BOC
• Mol File: 220731-04-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 330.167 °C at 760 mmHg
• Flash Point: 153.479 °C
• Appearance: /
• Density: 1.203 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.19±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(220731-04-4)
• EPA Substance Registry System: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(220731-04-4)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 220731-04-4(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C10H15N3O2. It is an ester of carbamic acid and 5-amino-2-pyridinyl, which is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients. It is a white to yellow solid that is soluble in organic solvents such as ethanol and methanol. This chemical compound is commonly used in research and development labs for the synthesis of new pharmaceutical compounds. It is important to handle and store this chemical compound with care, as it can be hazardous if not handled properly.

InChI:InChI=1/C10H15N3O2/c1-10(2,3)15-9(14)13-8-5-4-7(11)6-12-8/h4-6H,11H2,1-3H3,(H,12,13,14)

Upstream product

• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161117-88-0 (tert-butoxy)-N-(5-nitro(2-pyridyl))carboxamide 

Downstream Products

• 1361224-53-4 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1589534-97-3 5-(((3S)-4-(4-(methylsulfinyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589534-95-1 tert-butyl (5-(((3S)-4-(4-(methylcarbamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1589534-96-2 4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-methylbenzamide 
• 1572927-66-2 1-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)ethanone 
• 1589534-92-8 5-(((3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-methylethyl)phenyl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589534-91-7 5-(((3S)-4-phenyl-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589534-90-6 tert-butyl (5-(((3S)-4-phenyl-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1589535-24-9 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-4-hexyn-2-ol 
• 1589535-23-8 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-4-pentyn-2-ol 
• 1589535-22-7 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-3-methoxy-2-propanol 
• 1589535-21-6 3-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-4,4,4-trifluoro-3-hydroxybutanenitrile 
• 1589535-16-9 5-(((3S)-4-(4-(S-methylsulfonimidoyl)-phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589535-15-8 5-(((3S)-4-(4-(S-cyclopropylsulfonimidoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)-sulfonyl)-2-pyridinamine 

Relevant articles and documents

HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF

The application is directed to compounds of formula (IA) : and specifically compounds of formula (I) and their salts and solvates, wherein R1, R11, R12, R13, R4, R5, n, A1, A2, and A3 are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N′-arylpiperazine series

We have recently reported a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small molecule to its endogenous inhibitor, glucokinase regulatory protein (GKRP) these initial investigations culminated in the identification of 2-(4-((2S)-4-((6-amino-3- pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3, 3-hexafluoro-2-propanol (1, AMG-3969), a compound that effectively enhanced GK translocation and reduced blood glucose levels in diabetic animals. Herein we report the results of our expanded SAR investigations that focused on modifications to the aryl carbinol group of this series. Guided by the X-ray cocrystal structure of compound 1 bound to hGKRP, we identified several potent GK-GKRP disruptors bearing a diverse set of functionalities in the aryl carbinol region. Among them, sulfoximine and pyridinyl derivatives 24 and 29 possessed excellent potency as well as favorable PK properties. When dosed orally in db/db mice, both compounds significantly lowered fed blood glucose levels (up to 58%).